Drug Target Complex Belonging to the class B G-protein-coupled receptor, GLP-1R is a seven-transmembrane protein receptor (Figure 2)
These included: Low-dose tirzepatide (5mg/week) [OR = 0.64, 95% CI: 0.490.83] High-dose canagliflozin (300mg/day) [OR = 0.66, 95% CI: 0.520.84] Low-dose canagliflozin (100mg/day) [OR = 0.68, 95% CI: 0.520.89] High-dose tirzepatide (15mg/week) [OR = 0.72, 95% CI: 0.570.92] High-dose injectable semaglutide (2.4mg/week) [OR = 0.73, 95% CI: 0.580.91] Medium-dose tirzepatide (10mg/week) [OR = 0.73, 95% CI: 0.580.93] Medium-dose injectable semaglutide (1.0mg/week) [OR = 0.75, 95% CI: 0.570.97] Low-dose empagliflozin (110mg/day) [OR = 0.82, 95% CI: 0.700.97] Among all evaluated options, low-dose tirzepatide had the most favorable drop-out profile (eFigure 1 C, eFigure 2 C, eFigure 3G, and eTable 5 C)
They are recognized for their significant roles in wound healing, skin repair, and anti-aging processes
IUBMB Life 2005